Delving into the Latest Updates on Salus Therapeutics, Inc. with Synapse

Overview

In his article “A faster way to shut down genes” (News of the Week, 25 May, p. [1469][1]), R. John Davenport describes a promising technique called RNA interference for selectively silencing genes in a range of organisms. But in comparing the new approach to antisense methods, he makes a false assertion: “Fifteen years ago, antisense methods for gene silencing and gene therapy offered similar hopes, but that has been largely a bust.” Like any new method, antisense has faced significant and complex methodological and practical challenges since the first useful demonstration of this method in 1978. Although important issues remain, problems such as drug stability, deliverability, and targetting have been significantly addressed, if not solved. As evidence for these points, there are numerous successful companies that have been built partially or completely on antisense technology. Several have antisense drugs in the clinical pipeline that treat, for example, devastating forms of cancer and inflammatory disease. One antisense drug for the treatment of cytomegalovirus is in the market today. Monoclonal antibodies were trumpeted as new “miracle” drugs when the method to produce them first appeared nearly 30 years ago. They are just now appearing in the pharmaceutical market. Antisense has not been a “bust.” Rather, the development of antisense methods is following a characteristically difficult, expensive, and highly regulated path from laboratory to clinic. [1]: /lookup/doi/10.1126/science.292.5521.1469

1

News (Medical) associated with Salus Therapeutics, Inc.

17 May 2023

·www.globenewswire.com

Biotech Entrepreneur and Venture Capitalist Dinesh Patel Discusses Therapeutics and Medical Devices with CancerVAX CEO Ryan Davies

LEHI, Utah, May 17, 2023 (GLOBE NEWSWIRE) -- CancerVAX, developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today reported that the Company’s CEO, Ryan Davies, recently discussed the importance of developing new drugs and medical devices and their impact on the world of healthcare with biotech entrepreneur and venture capitalist Dinesh Patel. Dr. Patel founded TheraTech, a biotech company he took public and later sold to Watson Pharmaceuticals (now Abbvie). He then founded Salus Therapeutics, a biotech company focused on nucleic acid-based therapeutics, including gene therapy drugs and also founded Ashni Natraceuticals. Dr. Patel is the Chairman of the Utah Science Technology and Research Initiative (USTAR). He also serves as Executive Chairman of Xenocor and Chairman of the Board of Light Line Medical (both medical device companies) and is the co-founder and board member of New Eyes. Beyond his extensive career in the biotech space, Dr. Patel is also an active philanthropist actively helping many worthy organizations in the United States. Dr. Patel sits on the board of The Leonardo (a prestigious museum in Salt Lake City) and is a member of the board of the Utah Symphony & Opera. Dr. Patel was a founding partner of v-Spring Capital, a Utah-based venture capital firm active in biotech and high-tech sectors. Dr. Patel also continues to invest on a personal level through Patel Family Investments. “It was a delight speaking with Dinseh. I’ve known and admired him as an investor and biotech entrepreneur for many years,” said Ryan Davies, CancerVAX CEO. “His contributions to the world of medicine and healthcare are remarkable.” The Podcast can be viewed at: https://youtu.be/Um1Ca045Beg For more information about CancerVAX, please visit http:///www.cancervax.com/. About Us CancerVAX, Inc. is a pre-clinical biotechnology company developing a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer. Working with a team of experienced cancer researchers and physicians at UCLA, we intend to create a Universal Cancer Vaccine that will detect, mark, and destroy only the diseased cells with an incredibly high level of precision. Much like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, our cancer vaccine will leverage the body’s own immune system to destroy cancer cells. As we develop our universal cancer vaccine, we are also working with UCLA to develop single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. We look forward to the day when treating cancer will be as simple as getting a flu shot. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Press Contact:CancerVAX, Inc.Tel: (805) 356-1810info@CancerVAX.com

Vaccine

100 Deals associated with Salus Therapeutics, Inc.

Login to view more data

100 Translational Medicine associated with Salus Therapeutics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data